Company / Gross Margin
Emergent BioSolutions Inc. Gross Margin History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
30.3%
FY2023
5-year range
30.3% / 50.2%
FY2019-FY2023
Trend
-11.7%
vs FY2022
Sector context
#27 of 28
Health Care
What the data says
Among 28 Health Care companies, Emergent BioSolutions Inc. is in the bottom 4% for gross margin. Gross Margin has declined for 3 consecutive years, from 58.9% in FY2020 to 30.3% in FY2023.
Based on SEC 10-K filings.
30.3% in FY2023 with a 5-year CAGR of +32.2%.
Declined from 50.2% to 30.3% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -28.6pp
- 5-Year Change
- +32.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 28This company 30.3% Sector average 60.3%
▼
-49.8% below sector average
Key checks
Key Insights
- Emergent BioSolutions Inc.'s gross margin has declined for 3 consecutive years.
- In FY2023, gross margin decreased 11.7% year-over-year.
- Currently 30.0pp below the Health Care sector average.
- Peak gross margin was recorded in FY2020.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | 30.3% | -11.7% |
| FY2022 | 34.3% | -31.8% |
| FY2021 | 50.2% | -14.7% |
| FY2020 | 58.9% | - |
| FY2019 | - | - |
| FY2018 | -1.9% | -172.9% |
| FY2017 | 2.7% | -38.6% |
| FY2016 | 4.3% | - |
As of FY2023 · SEC 10-K · Updated Jul 2, 2026